We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s National Institute for Health and Care Excellence has recommended against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, saying benefits related to lung function were unlikely to be clinically significant. Read More
Johnson & Johnson and Novartis each scored a victory in the UK, with the National Institute for Health and Care Excellence backing their respective treatments for prostate cancer and heart failure. Read More
Small drugmaker Fabre-Kramer Pharmaceuticals won a big victory Thursday after the FDA ignored its own internal advisory committee recommendations and negative determinations by the Office of New Drugs’ Office of Drug Evaluation I. Read More